Irene Zaldívar, Zurko Research, Spain, is set to present on the topic during the upcoming Open Academy, due to be held in October in Barcelona, Spain and organised by the Cosmetics Consultants Europe industry association.
We caught up with her to gain insight into the content of her presentation, which will consider an overall perspective on why it is important to demonstrate the safety and efficacy of new cosmetic products by In Vitro and In Vivo studies. Zaldívar says the presentation will also cover innovative products with trending claims (maintenance of your skin microbiome, anti-pollution, etc.).
Meeting better informed consumers
Zaldívar notes that proving efficacy and safety has never been more important, as consumers are increasingly savvy and demanding claims proof.
“The current situation shows that cosmetic manufacturers compete in the global market with a big number of brands. Simultaneously, the potential consumers are more informed every day because of the internet,” she confirms.
“The current tendency of the industry is to focus on its products in segmented groups. For this reason, the research and development of new studies are keys for evaluating new cosmetic formulations.”
Moving forward, the testing expert suggests that close cooperation between the industry and its regulating bodies will continue to be essential.
“Claims versus evaluated products are one important difference between the products in the market. For this reason, the support of the claims should continue to be developed in co-operation between industry and regulatory institutions,” she confirms.
About the CCE Open Academy event
Set to take place in Barcelona, Spain, the Open Academy will see a series of eminent experts from across the industry Europe present on various hot topics.
The event spans one day, Monday 16th October, and includes sessions for networking alongside the extensive conference programme.
Highlights include presentations on non-animal testing methods for next generation ingredients, software tools for formulation and regulatory affairs, and CPR, REACH and Brexit. Futher information can be found here.